Hy-Vee Launches New Resource to Help Patients

Hy-Vee, Inc. is launching a new resource to help patients with diabetes who are covered under commercial/private insurance save on hundreds of insulin products at their local Hy-Vee Pharmacy.

Using a manufacturer-sponsored savings card, eligible patients with commercial/private insurance (or those without insurance who pay in cash) can get a 28-day supply of insulin for as a low as $35* per month at their Hy-Vee Pharmacy.

Patients can begin accessing and applying manufacturer-sponsored savings cards to their insulin prescriptions online by visiting hy-vee.com/healthnew/insulin before picking up their insulin prescription.

The manufacturer-sponsored savings cards are available to patients ages 18+ and accepted at all Hy-Vee Pharmacy locations. Once submitted online, the manufacturer-sponsored savings card will be automatically applied to future qualifying insulin prescriptions for up to 12 months at Hy-Vee Pharmacy.

“Our goal is to make it even easier for patients to manage their diabetes by increasing access to affordable insulin,” said Aaron Wiese, president of Hy-Vee, Inc. “By bringing more awareness to manufacturer-sponsored savings cards, we can help more patients save on their monthly insulin prescription at Hy-Vee Pharmacy."

Hy-Vee Pharmacy patients can quickly refill insulin prescriptions online or by contacting their local Hy-Vee Pharmacy. New patients can transfer to Hy-Vee Pharmacy online or by contacting a nearby Hy-Vee Pharmacy.

As part of President Biden’s historic Inflation Reduction Act, nearly four million seniors on Medicare with diabetes started to see their insulin costs capped at $35 per month this past January, saving some seniors hundreds of dollars for a month’s supply.

In March, Eli Lilly, the largest manufacturer of insulin in the United States started lowering their prices and meeting that call. Eli Lilly announced they are lowering the cost of insulin by 70% and capping what patients pay out-of-pocket for insulin at $35.

This action, driven by the momentum from the Inflation Reduction Act, could benefit millions of Americans with diabetes in all 50 states and U.S. territories. President Biden continues to call on Congress to finish the job and cap costs at $35 for all Americans.

*Some restrictions apply. Patients should see their pharmacy for additional eligibility details.